Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
During an investor presentation Nov. 7, the Swiss pharma outlined its plans to move lebrikizumab into Phase III next year.
You may also be interested in...
Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.